These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23684233)

  • 1. Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: role of the chirality on the biological activity.
    Marinozzi M; Carotti A; Sardella R; Buonerba F; Ianni F; Natalini B; Passeri D; Rizzo G; Pellicciari R
    Bioorg Med Chem; 2013 Jul; 21(13):3780-9. PubMed ID: 23684233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.
    Marinozzi M; Carotti A; Sansone E; Macchiarulo A; Rosatelli E; Sardella R; Natalini B; Rizzo G; Adorini L; Passeri D; De Franco F; Pruzanski M; Pellicciari R
    Bioorg Med Chem; 2012 Jun; 20(11):3429-45. PubMed ID: 22564381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous diastereo- and enantioseparation of farnesoid X receptor (FXR) agonists with a quinine carbamate-based chiral stationary phase.
    Sardella R; Marinozzi M; Ianni F; Lisanti A; Natalini B
    Anal Bioanal Chem; 2013 Jan; 405(2-3):847-62. PubMed ID: 22932813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
    Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
    Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M
    Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.
    Huang H; Yu Y; Gao Z; Zhang Y; Li C; Xu X; Jin H; Yan W; Ma R; Zhu J; Shen X; Jiang H; Chen L; Li J
    J Med Chem; 2012 Aug; 55(16):7037-53. PubMed ID: 22862148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.
    Fu J; Si P; Zheng M; Chen L; Shen X; Tang Y; Li W
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6848-53. PubMed ID: 23040732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR).
    Mehlmann JF; Crawley ML; Lundquist JT; Unwalla RJ; Harnish DC; Evans MJ; Kim CY; Wrobel JE; Mahaney PE
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5289-92. PubMed ID: 19683924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of fused 1,2,4-dithiazines and 1,2,3,5-trithiazepines.
    Koyioni M; Manoli M; Koutentis PA
    J Org Chem; 2014 Oct; 79(20):9717-27. PubMed ID: 25237713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
    Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
    Gioiello A; Macchiarulo A; Carotti A; Filipponi P; Costantino G; Rizzo G; Adorini L; Pellicciari R
    Bioorg Med Chem; 2011 Apr; 19(8):2650-8. PubMed ID: 21459580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marine sponge steroids as nuclear receptor ligands.
    Fiorucci S; Distrutti E; Bifulco G; D'Auria MV; Zampella A
    Trends Pharmacol Sci; 2012 Nov; 33(11):591-601. PubMed ID: 23000093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts.
    Id Boufker H; Lagneaux L; Fayyad-Kazan H; Badran B; Najar M; Wiedig M; Ghanem G; Laurent G; Body JJ; Journé F
    Bone; 2011 Dec; 49(6):1219-31. PubMed ID: 21893226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
    Yu DD; Lin W; Forman BM; Chen T
    Bioorg Med Chem; 2014 Jun; 22(11):2919-38. PubMed ID: 24775917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.
    Merk D; Steinhilber D; Schubert-Zsilavecz M
    Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.